Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- LEO Pharma, Hokkaido Univ. Pair Up to Identify Therapeutic Targets in Leukoplakia, Alopecia Areata
October 15, 2020
- Kyowa CritiCare Resumes Production of Soft Bag Products
October 14, 2020
- Shionogi Chief Says China JV Marks Pivot from Overly US-Focused Investments
October 14, 2020
- Big 4 Wholesalers Now Suspected to Have Rigged Drug Prices in 2016 Too
October 14, 2020
- Padcev Shows Positive PII Results for Urothelial Cancer Patients Ineligible for Cisplatin: Astellas
October 14, 2020
- Ono Licenses Epilepsy Med from South Korean Biopharma
October 14, 2020
- J&J Pauses COVID-19 Vaccine Trials, Japan PI Too
October 14, 2020
- Janssen Japan Chief Chris Hourigan Taking Up New Role for APAC
October 14, 2020
- Big 4 Wholesalers Raided Again over Suspected Bid-Rigging
October 13, 2020
- Nippon Zoki Eyes Alzheimer’s as New R&D Focus, First Up Is Label Expansion for Pain Med
October 13, 2020
- Samsca IV Prodrug Shows Non-Inferiority to Oral Agent
October 13, 2020
- Nichi-Iko, Sanofi in Authorized Generic Pact for ComPlavin
October 13, 2020
- Keytruda Filed for Triple Negative Breast Cancer in Japan: MSD
October 13, 2020
- Kyorin Transfers IP Rights for Novel Immunomodulator to Irish Firm
October 13, 2020
- Despite Price Cuts, Dupixent Netting Bullish Sales to Become Sanofi’s New Flagship
October 12, 2020
- Kissei Out-Licenses Parkinson’s Med to Hong Kong’s Affamed
October 12, 2020
- Canagliflozin Approved in Indonesia: Mitsubishi Tanabe
October 12, 2020
- Takeda-Led Alliance Kicks Off Global PIII for COVID-19 Plasma Therapy
October 12, 2020
- Takeda, US Arrowhead Join Forces on Intractable Liver Disease Therapy
October 12, 2020
- Sumitomo Chemical, Sumitomo Dainippon Launch JV for Cell Therapy CDMO
October 12, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…